Colorectal Cancer Screening: How to Stop a Moving Target

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 6, 2012, Pages 570-572

  van Rossum, Leo G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GUAIAC;

CANCER MORTALITY; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; FECES ANALYSIS; HUMAN; OCCULT BLOOD TEST; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY;

ADENOMA; CLINICAL LABORATORY TECHNIQUES; COLORECTAL NEOPLASMS; HUMANS; MASS SCREENING;

EID: 84861325556     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.03.009     Document Type: Editorial

References (25)

1. Heresbach D., Manfredi S., D'Halluin P.N., et al. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 2006, 18:427-433.
2. Wilson J.M.G., Jungner G. Principles and practice of screening for disease. WHO Chron 1968, 22:473.
3. Lansdorp-Vogelaar I., van Ballegooijen M., Zauber A.G., et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009, 101:1412-1422.
4. Atkin W.S., Edwards R., Kralj-Hans I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375:1624-1633.
5. Hol L., van Leerdam M.E., van Ballegooijen M., et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2009, 59:62-68.
6. Segnan N., Senore C., Andreoni B., et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 2007, 132:2304-2312.
7. Edwards J.T., Mendelson R.M., Fritschi L., et al. Colorectal neoplasia screening with CT colonography in average-risk asymptomatic subjects: community-based study. Radiology 2004, 230:459-464.
8. Heinrich H.C., Kamal R., Leberecht P. Ultrasensitive latex-agglutination-test for the specific immunochemical detection and quantification of fecal occult blood-loss. Klin Wochenschr 1983, 61:765-767.
9. Songster C.L., Barrows G.H., Jarrett D.D. Immunochemical detection of fecal occult blood: the fecal smear punch-disc test-a new non-invasive screening-test for colorectal-cancer. Cancer 1980, 45:1099-1102.
10. Levi Z., Rozen P., Hazazi R., et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007, 146:244-255.
11. van Rossum L.G., van Rijn A.F., Laheij R.J., et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008, 135:82-90.
12. van Rossum L.G., van Rijn A.F., Laheij R.J., et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009, 101:1274-1281.
13. Imperiale T.F. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future?. Ann Intern Med 2007, 146:309-311.
14. Crotta S., Segnan N., Paganin S., et al. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 2012, 10:633-638.
15. van Rossum L.G., van Rijn A.F., van Munster I.P., et al. Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests. Neth J Med 2009, 67:182-186.
16. Hundt S., Haug U., Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009, 150:162-169.
17. Nakama H., Yamamoto M., Kamijo N., et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999, 46:228-231.
18. Atkin W. Options for screening for colorectal cancer. Scand J Gastroenterol Suppl 2003, 38:13-16.
19. Imperiale T.F., Glowinski E.A., Lin-Cooper C., et al. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 2008, 359:1218-1224.
20. Wet bevolkingsonderzoek: versnelde herhaalde screening op darmkanker 2012, Gezondheidsraad, Gezondheidsraad, Den Haag, Netherlands.
21. Levi Z., Rozen P., Hazazi R., et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 2009, 104:933-938.
22. van Oijen M.G., Dieleman J.P., Laheij R.J., et al. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol 2008, 6:309-313.
23. Duffy M.J., van Rossum L.G., van Turenhout S.T., et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011, 128:3-11.
24. Berg M., Søreide K. Genetic and epigenetic traits as biomarkers in colorectal cancer. Int J Mol Sci 2011, 12:9426-9439.
25. Choong M.K., Tsafnat G. Genetic and epigenetic biomarkers of colorectal cancer. Clin Gastroenterol Hepatol 2012, 10:9-15.